Evaxion A/s income statement

In fiscal 2025, Evaxion A/s reported revenue of $7.5m, up 125.1% on the year before, operating income of −$9.2m (a -122.7% margin) and net income of −$7.7m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evaxion A/s: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	3	8
Research and development	17	12	10	10
Operating income	−25	−22	−15	−9
Interest expense	0	0	0	0
Income before tax	−24	−23	−11	−9
Income tax	−1	−1	−1	−1
Net income	−23	−22	−11	−8
Diluted EPS	−$24.50	−$20.25	−$10.00	—
Diluted shares (average)	—	1m	1m	6m
EBITDA	−25	−22	−14	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EVAX vs ROIV ADAG vs EVAX EVAX vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evaxion A/s's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evaxion A/s.